Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Liver Neoplasms × camrelizumab × Clear all

Phase

Phase 2 3 Phase NA 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3 Uterine Cervical Neoplasms 1 Pancreatic Neoplasms 1 Non-squamous Non-small Cell Lung Cancer 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Liver Neoplasms 1 Hodgkin Disease 1 Hepatoblastoma 1 Breast Neoplasms 1 Advanced Solid Tumor 1 Adenocarcinoma 1

Interventions

Sorafenib 3 lenvatinib 2 sintilimab 1 pembrolizumab 1 halofantrine 1 camrelizumab 1 Tranexamic Acid 1 Sunitinib 1 Standard of Care 1 Saline Solution 1 Oxaliplatin 1 Nadroparin 1 Lidocaine 1 Injections 1 Immune Checkpoint Inhibitors 1 Heparin, Low-Molecular-Weight 1 Gemcitabine 1 Folfox protocol 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05322187 2022-04-11

sPLENTY-pc

RenJi Hospital

Phase 2/3 Unknown

Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡